| Dr Laura Armstrong Pace, MD, PHD | |
|
295 S Chipeta Way, Salt Lake City, UT 84108-1287 | |
| (801) 581-4390 | |
| Not Available |
| Full Name | Dr Laura Armstrong Pace |
|---|---|
| Gender | Female |
| Speciality | Medical Genetics - Ph.d. Medical Genetics |
| Location | 295 S Chipeta Way, Salt Lake City, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104142025 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 8153511-1205 (Utah) | Secondary |
| 207SG0205X | Medical Genetics - Ph.d. Medical Genetics | 8153511-1205 (Utah) | Primary |
| Entity Name | University Of Utah Adult Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Two key elements necessary to turn this public data resource into better health and financial reward are 1) a robust private/public partnership and 2) a rethinking of the traditional roles of doctors and patients, who are increasingly taking greater responsibility for making decisions about their care.
20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.
› Verified 7 days ago
| Entity Name | Metrodora Asc Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1043955602 PECOS PAC ID: 4981070307 Enrollment ID: O20221026000512 |
News Archive
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Two key elements necessary to turn this public data resource into better health and financial reward are 1) a robust private/public partnership and 2) a rethinking of the traditional roles of doctors and patients, who are increasingly taking greater responsibility for making decisions about their care.
20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.
› Verified 7 days ago
| Entity Name | Metrodora Clinic, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124762281 PECOS PAC ID: 8628430766 Enrollment ID: O20230822000226 |
News Archive
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Two key elements necessary to turn this public data resource into better health and financial reward are 1) a robust private/public partnership and 2) a rethinking of the traditional roles of doctors and patients, who are increasingly taking greater responsibility for making decisions about their care.
20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura Armstrong Pace, MD, PHD 295 S Chipeta Way, Salt Lake City, UT 84108-1287 Ph: (203) 858-8679 | Dr Laura Armstrong Pace, MD, PHD 295 S Chipeta Way, Salt Lake City, UT 84108-1287 Ph: (801) 581-4390 |
News Archive
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Two key elements necessary to turn this public data resource into better health and financial reward are 1) a robust private/public partnership and 2) a rethinking of the traditional roles of doctors and patients, who are increasingly taking greater responsibility for making decisions about their care.
20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.
› Verified 7 days ago